AstraZeneca remains a long-term Buy despite recent setbacks, underpinned by robust product and pipeline strength. AZN targets $80bn in revenues by 2030, supported by 14 current blockbusters and a pipeline potentially adding 12 more by the decade's end. Recent pipeline wins in oncology, respiratory, and immunology offset the eplontersen ATTR-CM study failure and Farxiga's US LOE.

The U.S. Food and Drug Administration (FDA) on Thursday granted accelerated approval to AstraZeneca Plc's (NYSE:AZN) Ultomiris (ravulizumab) to lower proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of disease progression.

AZN wins accelerated FDA approval for Ultomiris in IgA nephropathy, marking the fifth approved indication for the drug in the United States.

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca today announced the US availability of ZEGFROVY® (sunvozertinib) for the treatment of adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, and whose disease has progressed on or after platinum-based chemotherapy.1 The US Food and Drug Administration granted accelerated approval to ZEGFROVY based on res.

AstraZeneca says FDA approves drug for rare kidney disease in adults

Novo Nordisk's CagriSema delivers 25% weight loss in women, spotlighting three ETFs for diversified exposure to the sector's growth.

AstraZeneca (AZN) has more clinical evidence behind Tezspire's expansion. The commercial payoff still needs proving. Shares traded at $168.38, up approximately

AstraZeneca Plc (NYSE:AZN) and Amgen Inc. (NASDAQ:AMGN) on Tuesday shared full results from the Phase 3 CROSSING trial of Tezspire (tezepelumab) in adolescents and adults with uncontrolled eosinophilic esophagitis (EoE).